Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer – Medical Xpress
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic cast…
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
-
Noosa News24 hours agoStar Entertainment signs $300m lifeline deal with US gaming giant Bally’s
-
Noosa News24 hours agoCopperString transmission line projected to cost almost $14b amid massive blowout
-
General23 hours agoMyanmar earthquake rescue efforts wind down as death toll hits 3,600
-
Business23 hours agoshould I buy hedged or unhedged ASX US-focused ETFs?